Phenomics Leadership Team


James S. Burns, DLS, MS, MBA, Co-Founder, Chairman & President - Served previously as Chairman, President & CEO of Assurex Health, Inc., a precision medicine company focused on treatment decision support products for patients with neuropsychiatric and pain disorders.  Dr. Burns has extensive experience as a founder, senior executive, and venture capitalist in translational research, development and commercialization of life sciences technology, including novel pharmaceuticals, stem cells, genetic therapy, monoclonal antibodies, flow cytometry, DNA sequencing, cancer drug development, tissue transplantation, and pharmacogenomics.

Brian D. Athey, Ph.D., FACMI; Co-Founder, Director, Chief Science and Technology Officer - Serves as the Michael Savageau Collegiate Professor and Chair of the Department of Computational Medicine and Bioinformatics (DCMB), Professor of Psychiatry, and of Internal Medicine at the University of Michigan Medical School. Founding Co-Director of the Michigan Institute for Data Science (MIDAS), Dr. Athey also serves as a special advisor for life and health sciences to the Academic VP/Provost of the Chinese University Hong Kong Shenzhen (CUHK-SZ) and is a Fellow of the Shenzhen Research Institute for Big Data (SRIBD). 

Gilbert S. Omenn, M.D., Ph.D, Director and Chair, Scientific Advisory Board (SAB) - The Harold T. Shapiro Distinguished University Professor of Computational Medicine and Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He served previously as the Chief Executive Officer of the University of Michigan System, Dean of Public Health at the University of Washington, and was a longtime board director of Amgen.  He has also served as associate director of the White House Office of Science and Technology Policy (OSTP), and is a long-standing member of the National Academy of Medicine. Dr. Omenn's research interests focus on differential expression of alternative splice isoforms of proteins and transcripts.


Pamela Weir, MBA, EVP, Chief Operating Officer, Director - Pamela joined Phenomics Health in 2020 as EVP, Chief Operating Officer and Board Director.  She has over 30 years of pharmaceutical experience across Commercial functions as well as R&D, Operations, Business Development and General Management. Pamela has extensive leadership and launch experience in global & U.S. markets, with primary care, hospital and specialty products across numerous therapeutic areas.  Prior to joining Phenomics, Pamela was the President & CEO of Precera Bioscience, which was acquired by Phenomics.   Her previous biopharma postings were President & COO for ContraMed and Chief Operating Officer for Medicines360.  Pamela’s prior positions were Vice President of Marketing for Alpharma (King) Pharmaceuticals and Nycomed Pharmaceuticals. She also held commercial leadership positions in Bayer and RPR (Sanofi).